Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in December

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 15th total of 232,000 shares. Currently, 2.7% of the shares of the stock are short sold. Based on an average daily volume of 322,600 shares, the days-to-cover ratio is presently 1.7 days.

Institutional Trading of Aadi Bioscience

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Aadi Bioscience in the third quarter valued at approximately $32,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Aadi Bioscience in the second quarter valued at approximately $37,000. Finally, BML Capital Management LLC acquired a new position in Aadi Bioscience during the third quarter worth $4,120,000. 52.08% of the stock is owned by institutional investors.

Aadi Bioscience Stock Down 1.7 %

AADI stock traded down $0.05 during trading on Tuesday, hitting $2.97. The company had a trading volume of 42,951 shares, compared to its average volume of 364,463. The firm has a 50-day moving average price of $2.61 and a 200-day moving average price of $2.03. Aadi Bioscience has a 12 month low of $1.21 and a 12 month high of $3.81. The stock has a market cap of $73.20 million, a price-to-earnings ratio of -1.30 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.46). Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. The company had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. During the same quarter in the previous year, the company posted ($0.60) earnings per share. Equities analysts expect that Aadi Bioscience will post -1.78 EPS for the current year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.